China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering

Group 1 - China SXT Pharmaceuticals Inc. has entered into a definitive agreement for the purchase and sale of 66,666,666 Class A ordinary shares at a price of $0.15 per share in a registered direct offering [1] - The aggregate gross proceeds from this offering are expected to be approximately $10 million, with the transaction expected to close on or about January 12, 2026 [2] - The offering is being made pursuant to a shelf registration statement on Form F-3 that became effective on December 1, 2025, and a final prospectus supplement will be filed with the SEC [3] Group 2 - China SXT Pharmaceuticals Inc. is an innovative pharmaceutical company founded in 2005, focusing on the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces [5]